INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025

NervGen: Data For Spinal Cord Injury Treatment Candidate Likely For Mid-2025

Tiziana Life Sciences: Awaiting Data Of Foralumab For Secondary Progressive Multiple Sclerosis

Cardiff Oncology: Beats Standard Of Care In First-Line Metastatic Colorectal Cancer

Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off

BriaCell Therapeutics: High-Potential In Phase 3 Metastatic Breast Cancer, But Financing Concerns

Annovis Bio: Funding May Be An Issue For Announced Phase 3 Trials

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex

Cognition Therapeutics: Shines Less Bright After Phase 2 Results In Alzheimer's Disease

Annovis: Strong Sell Reiteration Prior To Phase 3 Data In Parkinson's Disease

Pluri: Biotech Play With Several Opportunities Across Different Sectors

Eli Lilly: The Road To Approval Of Donanemab Is Open

Coya Therapeutics: Potential Milestone For The Treatment Of Alzheimer's This Summer

Coya Therapeutics: Potential Milestone For The Treatment Of Alzheimer's This Summer

P3 Health Partners: Moving In The Right Direction In 2024

Denali: Cash, Big Pharma Partnerships And High Potential For MPS-II Do Not Warrant A Buy

Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential

Intensity Therapeutics: A Bargain For A Late-Stage Company With A Remarkable Oncology Drug

Annovis Bio: Alzheimer's Phase 2/3 Topline Readout Puts Future For Buntanetap Into Question

Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's

enVVeno: The Road To Approval Seems Open From Here On

Gain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential

BioVie: Upcoming Phase 3 Readout In Alzheimer's May Create Significant Value

Cassava Sciences: My Bullish Take On Biomarkers And CTAD Data